🔬 Experts discuss platforms for industrializing cell therapy, machine-learning-assisted clone selection, microbioreactors for modeling large-scale processes, and streamlined process analytical technology.
📊 These options can boost production and achieve a state of readiness in biomanufacturing.
🚀 The goal is to have a reliable and scalable platform from the start.
🧪 Artificial intelligence can help predict clone performance in intensified processes.
🌱 Clones optimized for fed-batch processes may not be ideal for perfusion processes.
⚙️ True perfusion processes should start with clones optimized for perfusion conditions.
Introduction:
Upstream bioprocessing, which includes the production of cells and proteins for therapies, can be intensified and made more stable through the use of advanced monitoring and control technologies. This article explores several platforms and approaches that can help optimize upstream bioprocessing, including industrializing allogeneic cell therapy, using machine learning for clone selection, modeling large-scale perfusion processes, and implementing process analytical technology with spectroscopy data.
- Cell therapies can become more accessible if technology platforms are developed to accelerate the industrialization of allogenic cell therapies. These platforms should include systems for monitoring processes, flexible and automated equipment, digitalized processes, a comprehensive ecosystem for manufacturing, and highly specialized personnel.
- Machine learning can be used to predict the performance of clones in intensified processes. By training an artificial intelligence model with data from intensified fed-batch processes, top performing clones can be identified more accurately.
- Starting with clones optimized for perfusion processes can lead to better productivity in true perfusion bioreactors. Simulated assays can help identify top candidates, but true perfusion systems, like MilliporeSigma’s Mobius Breez, provide better scalability and process control.
Conclusion:
By implementing advanced technologies and platforms, biomanufacturers can achieve process intensification and stability in upstream bioprocessing. This can lead to increased production and improved accessibility of cell and gene therapies. Further advancements in monitoring and control technologies will continue to optimize upstream bioprocessing and drive innovation in the field.
